There are currently 1015 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Oregon Medical Research Center, Portland, Oregon
Conditions: Moderate to Severe Genital Psoriasis
Register for Updates
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
NCT06233799
Recruiting
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/19/2025
Locations: CODA, Portland, Oregon
Conditions: Methamphetamine-dependence, Methamphetamine Abuse
Register for Updates
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Portland, OR, Portland, Oregon
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259
Recruiting
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059
Recruiting
This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hearing Loss
Register for Updates
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200
Recruiting
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/16/2025
Locations: Anthos Investigative Site 1075, Portland, Oregon
Conditions: Atrial Fibrillation (AF)
Register for Updates
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT04576117
Recruiting
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
05/16/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Recurrent Low Grade Astrocytoma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Recurrent WHO Grade 2 Glioma, Refractory WHO Grade 1 Glioma
Register for Updates
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Kaiser Permanente-Northwest Region, Portland, Oregon
Conditions: Early Breast Cancer
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Legacy Emanuel Hospital & Health Center, Portland, Oregon
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04840589
Recruiting
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Register for Updates
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
NCT06088290
Recruiting
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Leiomyosarcoma
Register for Updates
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
NCT06528210
Recruiting
This phase II trial tests how well pembrolizumab along with standard of care androgen deprivation therapy, with bicalutamide and gonadotropin releasing hormone agonist, and radiotherapy for the treatment of patients with high risk prostate cancer that has not spread to other parts of the body (localized). A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Bic... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Register for Updates